Research Paper Volume 14, Issue 12 pp 5223—5232
The efficacy of adding hyperthermia to the treatment of advanced NSCLC patients based on the states of EGFR
Figure 4. The PFS of adding hyperthermia in first-line and posterior-line treatment (P>0.05).
Figure 4. The PFS of adding hyperthermia in first-line and posterior-line treatment (P>0.05).